Veru (STU:FMW) Change In Payables And Accrued Expense : €-17.02 Mil (TTM As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Veru Change In Payables And Accrued Expense?

Veru's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2024 was €-1.88 Mil. It means Veru's Accounts Payable & Accrued Expense declined by €1.88 Mil from Dec. 2023 to Mar. 2024 .

Veru's Change In Payables And Accrued Expense for the fiscal year that ended in Sep. 2023 was €-19.48 Mil. It means Veru's Accounts Payable & Accrued Expense declined by €19.48 Mil from Sep. 2022 to Sep. 2023 .

Veru Change In Payables And Accrued Expense Historical Data

The historical data trend for Veru's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Veru Change In Payables And Accrued Expense Chart

Veru Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

1.77

-1.07

4.12

27.06

-19.48

Veru Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-2.44	-7.91	-6.14	-1.10	-1.88

Veru Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-17.02 Mil.

Veru Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Veru's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Veru (STU:FMW) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Veru Inc (STU:FMW) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

VERU:USA FMW:Germany

Address

2916 North Miami Avenue, Suite 1000, Miami, FL, USA, 33127

Website

https://www.verupharma.com

Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology and acute respiratory distress syndrome (ARDS). The company is also in the late stage development of certain drugs for management of breast and prostate cancers. It also has a sexual health program which includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in single segment and generates revenue from USA which is the key revenue generating market, South Africa and other regions.

Veru (STU:FMW) Headlines

No Headlines